Passage Bio Inc. (NASDAQ: PASG) terminated its research collaboration agreement with Gemma Biotherapeutics Inc., providing written notice on May 21, 2026, according to a company statement.

The collaboration agreement, originally signed on July 31, 2024, involved Gemma conducting preclinical and Investigational New Drug-enabling work for Passage Bio's Huntington's disease research program and a paused Temporal Lobe Epilepsy program. Gemma had also granted Passage Bio options to conduct research programs in four central nervous system indications.

Separately, Passage Bio agreed to terminate its office lease at 2005 Market Street in Philadelphia, paying a $2.3 million termination fee to landlord Commerce Square Partners – Philadelphia Plaza, L.P. The termination agreement was executed on May 22, 2026.

The lease covered approximately 37,000 square feet of office space and was scheduled to run from February 2021 through December 2031. Passage Bio had subleased substantially all of the office space through two agreements executed in August and September 2023.

The information was disclosed in a company statement based on regulatory filings. The original collaboration agreement was previously filed as an exhibit to the company's quarterly report in November 2024.